<unk> , sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia. The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in ≥ 5% of people who received<unk>  were infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension.
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Ranibizumab
Ponatinib
Bevacizumab
Ruxolitinib
Dasatinib
Imatinib